Neupogen
Executive Summary
Amgen's granulocyte colony-stimulating factor (filgrastim) is not an orphan drug, the firm pointed out in a Sept. 23 letter to "The Pink Sheet." "In fact, the drug's approved indication [for febrile neutropenia associated with chemotherapy] precludes it from being covered by the Orphan Drug Act," Amgen said. The patient population for Neupogen is estimated by the firm to be in the 200,000-400,000 range. The letter from Amgen was in response to a reference by the National Organization for Rare Disorders to the orphan designation of Neupogen as an example of an abuse of the law ("The Pink Sheet"Sept. 2, T&G-2). . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth